Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Clin Exp Reprod Med. 2017 Mar;44(1):1-7. English. Review. https://doi.org/10.5653/cerm.2017.44.1.1
Sung N , Han AR , Park CW , Park DW , Park JC , Kim NY , Lim KS , Shin JE , Joo CW , Lee SE , Kim JW , Lee SK , .
Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Department of Obstetrics and Gynecology, Gangseo Mizmedi Hospital, Seoul, Korea.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
Department of Obstetrics and Gynecology, Gangnam Mizmedi Hospital, Seoul, Korea.
Maria Fertility Hospital, Seoul, Korea.
Department of Obstetrics and Gynecology, Bundang CHA Medical Center, CHA University, Seongnam, Korea.
Seoul Rachel Fertility Center, Seoul, Korea.
Department of Obstetrics and Gynecology, Konyang University College of Medicine, Daejeon, Korea. immune2015@naver.com sklee@kyuh.ac.kr
Abstract

The task force of the Korean Society for Reproductive Immunology recommends intravenous immunoglobulin G treatment in women with reproductive failure, including recurrent pregnancy loss and/or repeated implantation failure, who show cellular immune factors such as abnormal natural killer cell levels, natural killer cell cytotoxicity, and/or type 1 T helper immunity.

Copyright © 2019. Korean Association of Medical Journal Editors.